Heat Biologics Stock Today

HTBX -  USA Stock  

USD 3.03  0.06  1.94%

Market Performance
0 of 100
Odds Of Distress
Less than 18
Heat Biologics is trading at 3.03 as of the 16th of January 2022; that is -1.94 percent decrease since the beginning of the trading day. The stock's open price was 3.09. Heat Biologics has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Heat Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of December 2021 and ending today, the 16th of January 2022. Click here to learn more.
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patients immune system against cancer through T-cell activation and expansion. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina. The company has 25.4 M outstanding shares of which 1.17 M shares are currently shorted by private and institutional investors with about 4.43 trading days to cover. More on Heat Biologics

Heat Biologics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Heat Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Heat Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Heat Biologics generated a negative expected return over the last 90 days
Heat Biologics has high historical volatility and very poor performance
The company reported the previous year's revenue of 2.1 M. Net Loss for the year was (27.96 M) with loss before overhead, payroll, taxes, and interest of (9.99 M).
Heat Biologics currently holds about 108.91 M in cash with (33.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Heat Biologics has a frail financial position based on the latest SEC disclosures
Latest headline from www.nasdaq.com: Were Not Worried About IDEAYA Biosciences Cash Burn - Nasdaq
Heat Biologics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Heat Biologics SEC Filings
Heat Biologics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameHeat Biologics
Chairman of the Board, CEOJeffrey Wolf  (View All)
Average Analyst Recommendation
Analysts covering Heat Biologics report their recommendations after researching Heat Biologics' financial statements, talking to executives and customers, or listening in on Heat Biologics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Heat Biologics. The Heat Biologics consensus assessment is calculated by taking the average forecast from all of the analysts covering Heat Biologics.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Heat Biologics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Heat Biologics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares19.8 M18.4 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted19.8 M18.4 M
Significantly Up
Increasing
Slightly volatile
Total Assets154.1 M142.8 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities9.4 M10 M
Notably Down
Increasing
Slightly volatile
Current Assets141.2 M130.9 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities4.8 M4.2 M
Fairly Up
Increasing
Slightly volatile
Total Debt2.8 M2.1 M
Significantly Up
Increasing
Stable
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.04010.0391
Fairly Up
Increasing
Stable
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Heat Biologics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Heat Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Heat Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Heat Biologics' financial leverage. It provides some insight into what part of Heat Biologics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Heat Biologics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Heat Biologics deploys its capital and how much of that capital is borrowed.
Liquidity
Heat Biologics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.06 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Heat Biologics has a current ratio of 33.31, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(21.38 Million)Share
Heat Biologics (HTBX) is traded on NASDAQ Exchange in USA. It is located in 627 Davis Drive and employs 39 people. Heat Biologics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 78.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Heat Biologics's market, we take the total number of its shares issued and multiply it by Heat Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Heat Biologics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 25.4 M outstanding shares of which 1.17 M shares are currently shorted by private and institutional investors with about 4.43 trading days to cover. Heat Biologics currently holds about 108.91 M in cash with (33.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Heat Biologics Probability Of Bankruptcy
Ownership
Heat Biologics has a total of twenty-five million four hundred thousand outstanding shares. Heat Biologics retains 6.2 (percent) if its outstanding shares held by insiders and 6.2 (percent) owned by outside corporations . Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Heat Biologics Ownership Details

Heat Biologics Stock Price Odds Analysis

What are Heat Biologics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Heat Biologics jumping above the current price in 90 days from now is more than 94.0%. The Heat Biologics probability density function shows the probability of Heat Biologics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Heat Biologics has a beta of 0.0605. This usually indicates as returns on the market go up, Heat Biologics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Heat Biologics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Heat Biologics is significantly underperforming DOW.
 Odds Down 3.03HorizonTargetOdds Up 3.03 
6.10%90 days
 3.03 
93.88%
Based on a normal probability distribution, the odds of Heat Biologics to move above the current price in 90 days from now is more than 94.0 (This Heat Biologics probability density function shows the probability of Heat Biologics Stock to fall within a particular range of prices over 90 days) .

Heat Biologics Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Heat Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Heat Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Heat Biologics' value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares1.1 M6.7 M
Blackrock IncCommon Shares475.6 K2.8 M
Simplex Trading LlcCall Options78.1 K535 K
View Heat Biologics Diagnostics

Heat Biologics Historical Income Statement

Heat Biologics Income Statement is one of the three primary financial statements used for reporting Heat Biologics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Heat Biologics revenue and expense. Heat Biologics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Heat Biologics Interest Expense is fairly stable at the moment as compared to the past year. Heat Biologics reported Interest Expense of 631,813 in 2021. Selling General and Administrative Expense is likely to rise to about 18.5 M in 2022, whereas Consolidated Income is likely to drop (24.4 M) in 2022. View More Fundamentals

Heat Biologics Stock Against Markets

Picking the right benchmark for Heat Biologics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Heat Biologics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Heat Biologics is critical whether you are bullish or bearish towards Heat Biologics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Heat Biologics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Heat Biologics Corporate Directors

Heat Biologics corporate directors refer to members of a Heat Biologics board of directors. The board of directors generally takes responsibility for the Heat Biologics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Heat Biologics' board members must vote for the resolution. The Heat Biologics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Edward Smith - Independent DirectorProfile
John Monahan - Independent DirectorProfile
Louis Bock - Independent DirectorProfile
Paul Belsky - Independent DirectorProfile
Please check Risk vs Return Analysis. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Heat Biologics Stock analysis

When running Heat Biologics price analysis, check to measure Heat Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heat Biologics is operating at the current time. Most of Heat Biologics' value examination focuses on studying past and present price action to predict the probability of Heat Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heat Biologics' price. Additionally, you may evaluate how the addition of Heat Biologics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Heat Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heat Biologics. If investors know Heat Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heat Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heat Biologics is measured differently than its book value, which is the value of Heat Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Heat Biologics' value that differs from its market value or its book value, called intrinsic value, which is Heat Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heat Biologics' market value can be influenced by many factors that don't directly affect Heat Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heat Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heat Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heat Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.